Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder of aging plagued by progressive cognitive decline and memory loss. Its pathology is multifaceted, consisting of neuronal deficits, amyloid-beta (Aβ) peptides and plaque formation, neurofibrillary tangles, neuroinflammation, oxidative stress, and cerebrovascular dysregulation (Girouard and Iadecola, 2006; Gorelick et al., 2011; McGeer and McGeer, 2003; Serrano-Pozo et al., 2011) . The latter is characterized by early deficits in resting cerebral blood flow (CBF), neurovascular coupling, cerebrovascular reactivity, and endothelial cell function (Di Marco et al., 2015; Girouard and Iadecola, 2006; Gorelick et al., 2011) .
The risk of developing sporadic AD increases with each additional cardiovascular risk factor (de la Torre, 2010). Interestingly, many cardiovascular diseases have established therapeutic interventions and have modifiable risk factors. Focusing on the relationship between vascular pathology and AD may provide insight on pathways to prevent or delay AD (de la Torre, 2010). Since hypertension is the primary cardiovascular risk factor to AD, it is not surprising that the renin angiotensin system, the body's main blood pressure regulation system, is associated with AD. Cohort studies treated with antihypertensive medications either inhibiting angiotensin converting enzyme (ACE) cleavage of angiotensin I or antagonizing angiotensin II (AngII) type 1 receptors (AT1Rs) with angiotensin receptor blockers (ARBs) lowered the incidence and progression of AD (Khachaturian et al., 2006; Mogi and Horiuchi, 2009; Villapol and Saavedra, 2015) . ARB treatment in AD mouse models prevented and rescued cerebrovascular, neuropathological, and cognitive deficits, independent of their intended blood pressure lowering effects, and vary in their ability to alter amyloidosis (Ongali et al., 2014; Royea et al., 2017; Wang et al., 2007) .
Understanding the mechanism mediating ARBs pleiotropic benefits is fundamental in optimizing a therapeutic intervention strategy for AD. Chronic AT1R antagonism is suggested to favor conversion of AngII to angiotensin IV (AngIV), pointing to AngIV and its receptor AT4R, disputably corresponding to insulin-regulated aminopeptidase (IRAP) (Albiston et al., 2003; Wright et al., 2015) , as a potential target site (Braszko et al., 2006) . AT4Rs are distributed within brain structures predominantly used for cognitive processing, including the neocortex, hippocampus, and amygdala (Thomas and Mendelsohn, 2003) . Blocking AT4Rs previously counteracted cerebrovascular, anti-inflammatory, and cognitive benefits when concomitantly administered with an ARB in an AD mouse model (Royea et al., 2017) . These findings combined with the capacity of AngIV to acutely enhance cognitive function in rats (Braszko et al., 1988) , suggests that AngIV analogs https://doi.org/10. 1016/j.nbd.2019.104644 Received 26 April 2019; Received in revised form 1 October 2019; Accepted 16 October 2019 could be an attractive therapeutic target to combat cognitive and cerebrovascular impairments in AD. Despite decreased plasma or serum activity in enzymes involved in AngIV synthesis (Gard et al., 2017) , direct administration of AngIV or AngIV analogs has never been tested in well-characterized mouse models of AD. Here, we unambiguously demonstrate that selective and direct activation of brain AT4Rs counters AD cognitive and cerebrovascular deficits in face of a progressing Aβ pathology.
Materials and methods

Mouse model and treatment
We performed two independent experiments using two separate cohorts of wild-type (WT) and heterozygous transgenic C57BL/6 mice expressing an alternatively spliced human amyloid precursor protein (APP) minigene encoding hAPP695, hAPP751 and hAPP770 with the Swedish and Indiana familial AD mutations directed by the PDGF-βchain promoter (APP-J20 mice) (Mucke et al., 2000) . Mice were from our colony originally generated from breeders obtained from Dr. Lennart Mucke (Gladstone Institute of Neurological Disease and Department of Neurology at UCSF). Two separate cohorts of mice (4.5 months old) were implanted with osmotic minipumps (2.64 μl delivery/day; 35 days, Alzet, model: 1004) connected to a catheter implanted in the right lateral ventricle. The osmotic minipumps delivered either vehicle (aCSF) or AngIV (1.3 nmol/day; synthetic human AngII (3-8), Mimotopes, catalog 55200) at a steady state for 1 month. Cohort 1 consisted of WT (n = 10 (6F, 4M) aCSF; n = 9 (5F, 4M) AngIV) and APP (n = 10 APP (6F, 4M) aCSF; n = 12 (6F, 6M) AngIV) mice, while cohort 2 consisted of all male WT (n = 11 aCSF; n = 10 AngIV) and APP (n = 10 aCSF; n = 10 AngIV). The AngIV dose was selected based on the beneficial effects observed in apolipoprotein E-deficient mice (Vinh et al., 2008) . 5-bromo-2-deoxyuridine (BrdU,~1 mg/mouse/day; final 10 days, Sigma-Aldrich) was administered in the drinking water for neurogenesis investigations. Treatments did not influence survival. Experiments were approved by the Animal Ethics Committee of the Montreal Neurological Institute and met all guidelines of the Canadian Council of Animal Care. A schematic of the experimental timeline is depicted in Supplementary Fig. 1 .
Blood pressure (BP)
BP was measured by non-invasive tail-cuff plethysmography (Kent Scientific). Mice were habituated for 3 days prior to measurements. Ten acclimation cycles were performed prior to 5 experimental measurements. No differences were observed in systolic (119.0 ± 6.2 -126.0 ± 3.2 and 122.3 ± 6.8 -129.1 ± 4.3) or diastolic (95.9 ± 5.6 -101.4 ± 2.4 and 97.5 ± 3.0 -104.6 ± 3.7) measures across groups for cohorts 1 and 2, respectively.
Novel object recognition (NOR) test
Mice were habituated to an arena (white box; 70 x 70cm). Twentyfour hours after habituation, mice (n = 5 mice/group/cohort) explored identical objects (familiar) for 10 min. Following a 2 h delay, mice were presented with a familiar and novel object (equally interchanged, quadrant 2 or 4). Short-term memory was measured as a ratio of time interacting with the novel object divided by the time investigating the familiar object.
Morris water maze (MWM)
MWM1 was performed before treatment to confirm memory impairment. Familiarization consisted of 3 visible platform training days (3 daily trials, 60s/trial, 17 ± 1°C) in a room comprising 4 distal visuospatial cues. Cues and platform location were switched, and 5 days of consecutive learning commenced (3 daily trials, 90s/trial, platform 1 cm below water surface). On day 9, a probe trial (60s, platform removed) measured mouse recall. Following treatment, MWM2 was performed. Day 1 consisted of visible platform testing, followed by 5 days of hidden platform testing. Platform location and visuospatial cues were positioned to novel quadrants compared to MWM1. Mice underwent a probe trial on day 7. All MWM parameters were recorded using the 2020 Plus tracking system and Water 2020 software (Ganz FC62D video camera; HVS Image).
Laser doppler flowmetry (LDF)
A subset of mice from each cohort (n = 5-7/group/cohort, 2-3 males, 3-4 females for cohort 1) was used for investigating the increases in CBF evoked by whisker stimulation measured using LDF (Transonic Systems Inc.) (Tong et al., 2009) . Mice were anesthetized with ketamine (85 mg/kg, i.m.; Bioniche) and xylazine (15 mg/kg, i.m.; Haver). The bone over the left barrel cortex was thinned to translucency. Body temperature was maintained at 37°C using a rectal probe and heating pad (Harvard Apparatus). CBF measurements were recorded (4-5 stimulations/mouse) prior, during, and following contralateral stimulation of the right whisker pad (20s, 8-10 Hz, 30-40s intervals). The change in CBF was expressed as the percent increase relative to baseline.
Tissue preparation
Mice (n = 5 mice/group/cohort, 3 females, 2 males for cohort 1) were anesthetized (65 mg/kg of sodium pentobarbital, i.p.) and perfused intracardially using 4% paraformaldehyde (PFA). Brains were post-fixed (4% PFA, overnight), cryoprotected (30% sucrose, 48 h), frozen in isopentane (−30°C) and coronally sectioned on a freezing microtome (40 μm-thick sections from the right hemisphere for BrdU and cresyl violet cannula verification, 25 μm for the left intact hemisphere for remaining anatomical markers to avoid potential confounding effects of the inserted cannula in the analysis). Additional mice (n = 4 mice/group/cohort, 2 females, 2 males for cohort 1) were decapitated without anesthesia, their brains extracted, and the posterior cerebral arteries (PCAs) were isolated for cerebrovascular reactivity. Tissues (cortex and hippocampus) and pial vessels (n = 5 mice/group/cohort, 3 females, 2 males for cohort 1) were dissected from brains used for cerebrovascular reactivity and from remaining mice in each group, were frozen on dry ice and stored (−80°C) for further Western blot analyses, as detailed below.
Cerebrovascular reactivity
PCA segments were pressurized (60 mmHg) with Kreb's solution to test vasomotor responses using an on-line videomicroscopy system (Living Systems Instrumental) (Tong et al., 2009 ). Dilatations to acetylcholine (ACh, 10 −10 -10 −5 M; Sigma-Aldrich), calcitonin gene-related peptide (CGRP, 10 −10 -10 −6 M; American Peptide), transient potential vanilloid 4 (TRPV4) channel agonist GSK1016790A (GSK, 10 −11 -10 −5 M; Sigma-Aldrich), and KATP channel opener levchromakalim (LEV, 10 −9 -10 −4 M; Tocris) were tested by extraluminal application on pre-constricted vessels (phenylephrine, 2 × 10 −7 M; Sigma-Aldrich). Baseline production of nitric oxide (NO) was tested on vessels at resting tone by administration of the NO synthase (NOS) inhibitor N ω -nitro-L-arginine (L-NNA, 10 −5 M, 40 min; Sigma-Aldrich). Online measurements of the intraluminal diameter were performed using a closed-circuit video system (National Electronics) and video caliper (Image Instrumentation).
Western blot
Samples were sonicated in Laemnli buffer (62.5 mM Tris, pH 6.8, 6 M urea, 160 mM 1,4-DTT, 2% SDS, and 0.001% bromophenol blue), homogenized, centrifuged, and supernatants used for western blot experiments. Proteins were separated using SDS gels and transferred to nitrocellulose membranes. Membranes were incubated in 7% blocking buffer (1 h) and overnight with: mouse anti-AT1R (1:200) (Frei et al., 2001) , anti-AngII type 2 receptor (1:200, AT2R) (Frei et al., 2001) , anti-Aβ 1-16 antibody (1:1000; 6E10, Covance, SIG-39320), or anti-aldehyde oxidase (1:250, AOX1, Santa Cruz, sc-98500); rabbit anti-AT4R (insulin regulated aminopeptidase, IRAP, 1:500, Cell Signaling, 3808s), anti-superoxide dismutase 2 (SOD2, 1:3000, MnSOD, Ann Arbor, ADI-SOD-110-F), or anti-p67Phox (1:200, Abcam, 610912). Membranes were incubated using horseradish peroxidase-conjugated secondary antibody (1:2000; 1 h, Jackson ImmunoResearch). Mouse anti-β-actin (1:10,000; Sigma-Aldrich, A5441) standardized loading.
Immunohistochemistry
Brains were post-fixed, cryoprotected, frozen in isopentane and coronally sectioned on a freezing microtome (25 μm left hemisphere for anatomical markers or 40 μm right hemisphere for BrdU and cresyl violet cannula verification). Sections were immunostained for mature dense core (Thioflavin S, 1%, 8 min) and diffuse (anti-6E10; 1:800; Covance, SIG-39320) Aβ plaques, reactive astrocytes (anti-GFAP, 1:1000, DAKO, 6A524) or microglia (anti-Iba-1, 1:300, Wako), oxidative stress (1:400, anti-MnSOD, Stressgen, ADI-SOD-110-F), newborn cells (anti-BrdU, 1:400, overnight, Boehringer Mannheim, OBT00300X), neuronal progenitor cells (anti-Ki67, 1:1000, Leica Biosystems, PA0129) and immature neurons (anti-doublecortin, DCX, 1:200, Santa Cruz, cs-8066). Sections were incubated (30 min) with secondary anti-rabbit cyanine-2 (1:400) for immunofluorescence or biotynilated anti-mouse, −goat, or -rabbit (1:200; Vector Laboratories) secondary antibodies, followed by avidin-biotin complex, and visualized with 3,3′-diaminobenzidine or slate gray. Sections were mounted on gelatin-coated slides, coverslipped, and observed under light or fluorescence microscopy using a Leitz Aristoplan microscope equipped with epifluorescence (FITC filter).
Statistical analysis
All in vivo and vascular reactivity experiments were performed blind. Vascular responses were expressed as percent change in vessel diameter as a function of agonist concentration or duration of NOS inhibition. Agonist dose-response curves were generated with GraphPad Prism 7 and analyzed by repeated-measures ANOVA. Western blot membranes were developed and quantified using enhanced chemiluminescence with a phosphor Imager (scanner STORM 860, GE Health Care). Low-power digital images (2-3 sections/mouse, n = 5 mice/group) were manually delineated and quantified using Metamorph (6.1r3, Universal Imaging) for the percent cortical or hippocampal area occupied by Thioflavin S-and Aβ-positive plaques (bregma levels −1.46 to −1.70 mm), as well as by GFAP-(bregma levels −1.70 to −1.82 mm), Iba-1-(bregma levels −1.46 to −1.70 mm) and SOD2-(bregma levels 0.02 to −0.10 mm) positive elements. Iba-1 positive cells (10 cells/section/mouse, n = 5 mice/ group) were individually delineated and a skeleton analysis was performed to measure cell size (Young and Morrison, 2018) using ImageJ. For Neurogenesis, BrdU and Ki67 immunopositive nuclei in the subgranular zone (bregma levels −1.94 to −2.18 mm) were manually counted under the microscope. Length of the longest dendrites of DCX granule cells projecting in the molecular layer was divided by the layer thickness to measure the extent of their dendritic arborization. This was Fig. 1 . AngIV-treatment (T) improved cognitive function in APP mice. Treatment had no effect on discrimination ratios (treatment F(1, 16) = 0.001, p = .976; genotype F(1, 16) = 0.09, p = .775) during familiarization (A). AngIV restored shortterm memory deficits in APP mice to WT levels (treatment F(1, 16) = 11.23, p = .004; genotype F(1, 16) = 7.36, p = .015) (B). MWM1 confirmed spatial learning (day 5 t(54) = 5.87, p < .001) and memory retention deficits (time spent: t(54) = 4.22, p < .001; distance swam: t(54) = 4.19, p < .001; platform crosses: t(54) = 4.61, p < .001) in APP mice compared to WT, independent of swimming speeds (t(54) = 1.87, p = .067) (C-D). In MWM2, AngIV-treated APP mice (APPT) demonstrated improved spatial learning in the target quadrant compared to APP controls on the final day of hidden platform training (treatment F(1, 35) = 4.66, p = .039; genotype F(1, 35) = 12.91, p = .001) (E). In the probe, APPT mice displayed significantly increased platform crossings (treatment F(1, 35) = 3.42, p = .075; genotype F(1, 35) = 22.28, p < .001), time spent (treatment F(1, 35) = 5.65, p = .024; genotype F(1, 35) = 17.16, p < .001), and percent distance (treatment F(1, 35) = 5.30, p = .029; genotype F(1, 35) = 16.19, p < .001) within the target quadrant compared to APP controls (F). WT comparisons indicated by *, whereas APPT comparisons by *. Two-way ANOVAs (NOR) and repeated two-way ANOVAs (MWM2) were followed by Newman Keul's post-hoc multiple comparisons tests or student t-test. n = 10-12 mice/group (6-7 females, 4-6 males). *p < .05, **p < .01, ***p < .001. done by overlaying an image of a microscope accessory ruler taken at the same magnification as the DCX-labelled images. Data were analyzed by two-way ANOVA (factors being genotype: WT or APP and treatment: vehicle or AngIV) and, when ANOVA was significant, a Newman-Keul's multiple comparison test was performed. For two group analyses, a student t-test was used. All data are expressed as mean ± SEM. Analyses were performed using GraphPad7, and a p < .05 was considered significant. Statistical analysis is presented within the figure legends. No statistical analysis was performed to test for possible sex differences due to the small number of male or female mice in cohort 1. However, comparisons in previous studies did not yield significant difference in markers investigated, such that both sexes were always combined (Tong and Hamel, unpublished) . Cresyl violet staining was performed to verify that the cannula fully penetrated the cortical mantle and was positioned within the ventricle. Two mice in cohort 1 (1 male and 1 female) and none in cohort 2 were excluded for improper cannula implantation.
Results
AngIV rescued working memory deficits in APP mice
No preference was observed for familiar objects shown by similar discrimination ratios during pre-acquisition in the NOR test ( Fig. 1A  cohort 1 ). In contrast, APP mice failed to discriminate between familiar and novel objects, as shown by a novel object discrimination ratio lower than WT ( Fig. 1B for cohort 1) . This short-term memory deficit was prevented in AngIV-treated mice ( Fig. 1B for cohort 1) . Similar results were obtained for cohort 2 ( Supplementary Figs. 2A, B ).
AngIV improved spatial learning and normalized memory retention in APP mice
In MWM1, a student t-test comparing APP mice to WT revealed a significant deficit in spatial learning (Fig. 1C ) and memory retention (Fig. 1D) . Irrespective of the cohort, all mice exhibited proper visual and motor function during familiarization (Fig. 1C ) and probe trial (Fig. 1D ). Mice were then randomly divided for AngIV treatment or vehicle and, following 1 month of AngIV treatment, MWM2 was conducted. As assessed by repeated measures ANOVA, all groups performed similarly during visible platform training. During the hidden platform portion of the task, APP controls performed worse than all other groups and, on day 5 of testing, they exhibited a significantly longer escape latency than both WT and AngIV-treated APP mice, the latter displaying partial recovery as still different from WT (Fig. 1E ). In the probe trial, AngIV-treated APP mice performed better than APP controls, represented by a significantly greater time spent and distance swam within the target quadrant (Fig. 1F) ; and their performance compared to that of WT mice in all parameters. In cohort 2, AngIVtreated APP mice additionally performed significantly better than APP controls for the number of platform crossings during the probe trial ( Supplementary Fig. 2C ). AngIV had no effect on memory performance in WT mice, and all mice displayed similar swimming speed (Figs. 1E-F for cohort 1, Supplementary Fig. 2D for cohort 2).
AngIV augmented the number of newborn cells, cellular proliferation, and dendritic arborization of granule cells in the DG of APP-treated mice
Dysfunctional neurogenesis has been suggested to exacerbate neuronal vulnerability and contribute to memory impairment during AD (Ermini et al., 2008; Haughey et al., 2002) . Since AngIV rescued memory in APP mice, we investigated whether hippocampal neurogenesis was affected. We first explored whether AngIV influenced new cell formation and cellular proliferation in the DG as measured by the number of BrdU-or Ki67 immunoreactive cells. APP controls had reduced numbers of BrdU-positive cells ( Figs. 2A-B) , as well as newly proliferated Ki67-positive nuclei (Figs. 2C-D, Supplementary Fig. 2E ) in the DG compared to WT, as expected from previous reports (Ermini et al., 2008; Haughey et al., 2002) . AngIV-treated APP mice displayed significantly more BrdU ( Figs. 2A-B) and Ki67-positive cells (Figs. 2C-D, Supplementary Fig. 2E ) compared to APP controls. However, this recovery was incomplete as the number of positive nuclei were still reduced compared to WT ( Figs. 2A-D) . Both the number of immature DCX-immunopositive granule cells and extent of their dendritic arborization in the molecular layer of the DG were significantly reduced in APP mice compared to WT ( Figs. 2E-F, Supplementary Fig. 2F ). AngIV-(caption on next page) treatment did not prevent the loss of immature granule cells; yet, it fully normalized (Fig. 2F ) or significantly increased ( Supplementary Fig. 2F ) the dendritic arborization length of remaining DCX-positive cells to WT levels.
AngIV restored cerebrovascular reactivity and neurovascular coupling
The impaired dilatory responses to ACh and CGRP, and reduced baseline NO bioavailability (measured following NOS inhibition with L-NNA) in APP mice were normalized to WT levels in AngIV-treated APP mice (Figs. 3A-C). To further elucidate how these responses were restored, we tested both TRPV4 and KATP channels, respectively implicated in ACh-and CGRP-mediated dilatory responses (Tong et al., 2009; Vedernikov et al., 2002; Zhang et al., 2013a) . Both TRPV4 and KATP channels were severely impaired in APP mice compared to WT, a deficit countered by AngIV (Figs. 3D-E) . Additionally, the impaired neurovascular coupling response to whisker stimulation in APP controls was normalized to WT levels in AngIV-treated APP mice (Fig. 3F) . AngIV had no effect on dilatory responses and baseline NO bioavailability in WT mice. Similar results were obtained in cohort 2 (Supplementary Fig. 3A-C) .
AngIV reduced oxidative stress, but not neuroinflammation and amyloidosis
Aβ is known to induce oxidative stress (Esposito et al., 2006) . To investigate the relationship between AngIV and oxidative stress, we first measured SOD2 protein levels, the main superoxide scavenger in mitochondria. As previously shown, cortical ( Fig. 4A ) and hippocampal (Fig. 4B ) SOD2 protein levels were significantly increased in APP mice compared to WT (Ongali et al., 2014; Royea et al., 2017) , an upregulation completely abolished in AngIV-treated APP mice ( Figs. 4 A, B , Supplementary Fig. 4A ). Since superoxide production occurs via NADPH-oxidase (Park et al., 2005) , in part through the P67Phox subunit (Babior, 2004) and via aldehyde oxidase's (AOX1) involvement in hydrogen peroxide production (Kundu et al., 2007) , we examined whether AngIV altered these pathways in the hippocampus. AngIV significantly reduced P67Phox upregulation seen in APP mice ( Fig. 4B ) and tended to normalize the increase, albeit not significant, in AOX1 protein levels in APP mice compared to WT (Fig. 4B) . In contrast, AngIV-T had no effect on SOD2, P67Phox, and AOX1 expression in WT mice (Fig. 4) .
Fig. 2.
AngIV-treatment (T) stimulated newborn cell formation, cellular proliferation, and dendritic arborization in APP mice. APP mice had fewer newborn cells, cellular proliferation, and immature granule cell bodies with shorter dendrites than WT (A-F). AngIV significantly elevated newborn cell formation (A-B, BrdU) and cellular proliferation (C-D, Ki67) in the dentate gyrus of APP mice compared to controls (A-D). AngIV had no effect on the number of immature granule cell bodies; yet, dendritic length projecting in the molecular layer (ML) was significantly increased by AngIV (E-F, DCX). Two-way ANOVAs were followed by Newman Keul's post-hoc multiple comparisons tests. *p < .05, **p < .01, ***p < .001. n = 5 mice/group, 3 females, 2 males. Scale bars = 150 μm. F values: newborn cells (treatment F(1, 15) = 4.37, p = .054; genotype F(1, 15) = 54.71, p < .001; interaction F(1, 15) = 7.284, p = .017); cellular proliferation (treatment F(1, 15) = 2.94, p = .107; genotype F(1, 15) = 34.23, p < .001); immature granule cells (treatment F(1, 15) = 0.001, p = .974; genotype F(1, 15) = 29.80, p < .001); dendritic arborization (treatment F(1, 15) = 3.89, p = .067; genotype F(1, 15) = 6.18, p = .025). . 3 . AngIV-treatment (T) normalized vasodilatory function, NO bioavailability, and neurovascular coupling in APP mice. AngIV rescued ex vitro isolated posterior cerebral artery dilatory responses to ACh (treatment F(1, 12) = 30.18, p < .001; genotype F(1, 12) = 36.54, p < .001; interaction F(1, 12) = 36.63, p < .001) and CGRP (treatment F(1, 12) = 17.50, p < .003; genotype F(1, 12) = 24.58, p = .001; interaction F(1, 12) = 24.63, p = .001) of APP mice to WT (A-B) . AngIV restored the reduced production of baseline NO in APP mice to WT levels (treatment F(1, 12) = 5.42, p = .048; genotype F(1, 12) = 8.26, p = .021; interaction F(1, 12) = 7.93, p = .023) (C). AngIV also normalized TRPV4 (treatment F(1, 12) = 41.19, p < .001; genotype F(1, 12) = 41.97, p < .001; interaction F(1, 12) = 49.43, p < .001) and KATP (treatment F(1, 12) = 25.59, p = .001; genotype F(1, 12) = 29.10, p < .001; interaction F(1, 8) = 28.64, p < .001) channelmediated vasodilatory responses of APP mice (D-E). AngIV had no effect on dilatory responses or baseline NO bioavailability in WT mice. Impaired neurovascular coupling in APP mice was normalized by AngIV to WT levels (treatment F(1, 20) = 1.34, p = .273; genotype F(1, 20) = 5.63, p = .039; interaction F(1, 20) = 23.12, p < .001). Error bars indicate SEM, n = 4 mice/group (n = 2 females, n = 2 males) (A-E) and n = 5-7 mice/group (3-4 females, 2-3 males) (F). WT comparisons are indicated by * whereas APPT comparisons by *. Two-way ANOVAs were followed by Newman Keul post-hoc multiple comparisons tests.
Fig
AD pathogenesis also involves activation of inflammatory pathways, with some studies suggesting a reduced risk of developing AD when patients used anti-inflammatory drugs (McGeer et al., 1996) . Here, we assessed the anti-inflammatory properties of AngIV. GFAP immunopositive astrocytes (Figs. 5A-B) and Iba-1 immunopositive microglial cells (Figs. 5C-E) were significantly elevated in the somatosensory cortex of APP mice compared to WT, with larger and more ramified microglial cells (Fig. 5E) , responses that were unaffected by AngIV (Figs. 5A-B ), as also found in cohort 2 ( Supplementary Figs. 4B,  C) . Moreover, although amyloidosis is low at this age, cortical and hippocampal Aβ plaque load was measured by thioflavin S-positive dense core plaques (Fig. 6A ) and 6E10-immunopositive mature and diffuse Aβ plaques (Figs. 6B). AngIV did not significantly alter Aβ plaque load (Figs. 6A-B ). Correspondingly, in tissues from nonperfused mice, the APP protein and 56 kDa oligomeric species measured by Western blot within the pial vessels, cortex and hippocampus were comparable in all groups. The 9 kDa Aβ dimers, only detectable within the hippocampus in young APP mice (Royea et al., 2017; Tong et al., 2012) , were also not significantly different following AngIV intervention ( Figs. 6C-E) .
AngIV normalized altered hippocampal AT1R and AT4R protein levels selectively
AT1R protein levels were elevated in APP mice compared to WT mice in the cortex and hippocampus. AngIV reduced AT1R upregulation in APP mice, although significantly only in the hippocampus (Fig. 7A,  D) . No difference was observed in AT2Rs across conditions (Fig. 7B, E) . Similarly, cortical AT4Rs (quantified as IRAP), were not significantly different across groups (Fig. 7C) . In contrast, AT4Rs were significantly decreased in the hippocampus of APP mice compared to WT, a deficit normalized by AngIV in APP mice (Fig. 7F) .
Discussion
There is currently no available effective therapy to prevent, slow down or cure AD; however, the neurobiological links between RAS and AD have become a source of interest in the pathology of the disease. Understanding how ARBs can decrease the incidence and progression of AD may be crucial for optimizing pharmaceutical intervention for the treatment of this devastating disease. The present study sought to elucidate whether administrating AngIV, also known as AngII (3-8), could treat AD-related symptoms and affect classic AD biomarkers. Utilizing cognitive and cerebrovascular measures as indicators of clinical outcomes, our results highlight AngIV's ability to restore functionality in impaired APP mice. Remarkably, memory rescue coincided with AngIV's ability to reduce oxidative stress, and improve dendritic arborization of DG maturing granule cells, and normalize cerebrovascular function. Moreover, the latter concurred with restored NO bioavailability, endothelial and smooth muscle cell ion channel function, and neurovascular coupling. These benefits occurred irrespective of changes in Aβ pathology, neuroinflammation, and BP. Together our findings strongly argue for considering AngIV as a promising therapeutic target to combat AD and accelerating the development of AngIV analogs that can readily access the brain, as promising candidates in AD therapy.
Memory deficits in APP mice, AngIV benefits independent of Aβ pathology
Deficits in short-term memory, spatial learning, and memory retention were previously reported in APP mice (Ongali et al., 2014; Royea et al., 2017) . AngIV countered this phenotype without altering performance of WT mice, highlighting its role in cognitive rescue. Whereas our results showed no cognitive benefits in WT mice following chronic AngIV administration, previous studies reported enhanced memory in WT rodents following acute AngIV treatment (Braszko et al., 1988) . It is possible that the pro-cognitive benefits of acute AngIV treatment may dissipate following chronic treatment in WT mice, whereas they are maintained in pathological conditions as observed here in APP mice. Hence, it is the first time that the selective benefits of chronic AngIV treatment on lessened cognitive function are demonstrated in a well-characterized AD mouse model. Since the principal clinical feature of AD is memory impairment, our findings have compelling potential as a therapeutic target in AD.
Several mechanisms have been associated with memory dysfunction in APP mice and altered neurogenesis is one of interest considering its important role in memory processes (Ermini et al., 2008; Haughey et al., 2002; Kempermann et al., 2015) . In this regard, we confirmed a Fig. 4 . AngIV-treatment (T) reduced oxidative stress in APP mice. The percent surface area occupied by cortical SOD2 immunoreactive material was significantly higher in APP controls than WT, and normalized to WT levels by AngIV-treatment (treatment F(1, 14) = 124.70, p < .001; genotype F(1, 14) = 122.50, p < .001; interaction F(1, 14) = 76.39, p < .001) (A). Western blot analysis of hippocampal SOD2 (treatment F(1, 26) = 1.09, p = .31; genotype F(1, 26) = 7.23, p = .012) and P67Phox (treatment F(1, 12) = 2.43, p = .145; genotype F(1, 12) = 8.18, p = .014; interaction F(1, 12) = 18.88, p = .001) protein levels showed upregulation in APP mice compared to WT controls, which was normalized following AngIV intervention, while AOX1 levels were not significant altered across conditions (treatment F(1, 12) = 2.38, p = .149; genotype F (1, 12) = 6.95, p = .022) (B). AngIV-T had no effect on SOD2, P67Phox, and AOX1 protein levels in WT mice. Two-way ANOVAs were followed by Newman Keul's post-hoc multiple comparisons tests. n = 4-5 mice/group (3 females, 2 males). Scale bar = 150 μm. reduction of hippocampal newborn cells in APP mice (Royea et al., 2017) , but more importantly, we demonstrated AngIV's ability to increase newborn cell formation and proliferation in treated APP mice. Strikingly, AngIV normalized dendritic extension from residual maturing DCX neurons in the molecular layer of the DG, the most visible morphological feature of neuronal maturation that enables dendrites to receive perforant path input (Kempermann et al., 2015; Vago et al., 2007) , a critical pathway for memory retention and recall. Prior work demonstrating AngIV's ability to stimulate hippocampal spinogenesis and synaptogenesis (McCoy et al., 2013) , facilitate synaptic transmission, and enhance long-term potentiation in the DG (Wayner et al., 2001) , along with our findings strongly suggest that AngIV-mediated neuroprotection and neurogenesis contributed to cognitive rescue, without excluding other potential mechanisms not investigated in our study.
Interestingly, AngIV had no significant effect on Aβ pathology, confirming the ability to achieve cognitive rescue despite ongoing amyloidosis, as shown in AD mouse models with ARB losartan (Royea et al., 2017) and simvastatin (Tong et al., 2012) , and following Aβ 1-42 immunization in a clinical trial (Holmes et al., 2008) . Our results revealed no significant effect of one-month long AngIV administration on cerebral or cerebrovascular APP expression and processing, Aβ 56 kDa oligomeric species previously correlated with cognitive deficits in AD mice (Lesné et al., 2006) , 9 kDa Aβ dimers associated with disrupted long-term potentiation and memory impairment in rodents (Walsh et al., 2002) , and cortical and hippocampal Aβ plaque load at an early stage in the pathogenesis. Whether or not a longer AngIV treatment would significantly reduce amyloidosis cannot be excluded, as well as whether AngIV treatment possesses effects on soluble Aβ species.
AngIV, inflammation, and oxidative stress
Neuroinflammation, oxidative stress and mitochondrial dysfunction are associated with neuronal and vascular alterations in AD patients (Gorelick et al., 2011; McGeer and McGeer, 2003; Serrano-Pozo et al., 2011) and APP mice (Esposito et al., 2006; Ongali et al., 2014; Park et al., 2011; Royea et al., 2017) . Prior work antagonizing AT1Rs reduced neuroinflammation in APP mice (Ongali et al., 2014) , a response prevented by AT4R antagonism (Royea et al., 2017) . In contrast, AngIV did not counter neuroinflammation evaluated anatomically through GFAP-positive astrocytes and Iba1-positive microglial cells. This is consistent with its previously reported pro-inflammatory role, albeit in Fig. 5 . AngIV-treatment (T) did not alter neuroinflammation in the somatosensory cortex of APP mice. The surface area occupied by GFAP immunopositive astrocytes (A,B; treatment F(1, 12) = 1.19, p = .297; genotype F(1, 12) = 90.55, p < .001) and Iba-1 immunostained microglial cells (C,D; treatment F(1, 16) = 0.62, p = .442; genotype F(1, 16) = 22.23, p < .001) were significantly elevated in APP mice compared to WT, an effect unaltered by AngIV-treatment. Iba-1 positive cells in APP mice were significantly larger than those in WT mice, and AngIV-treatment did not reduce microglial cell size (E, treatment F(1, 16) = 0.08, p = .77; genotype F(1, 16) = 91.85, p < .001. Two-way ANOVAs were followed by Newman Keul's post-hoc multiple comparisons tests. n = 4-5 mice/group. Scale bar = 500 μm. Fig. 6 . AngIV-treatment (T) did not alter amyloid pathology in APP mice. Cortical (Co) and hippocampal (Hi) surface areas occupied by dense core (A, thioflavin S, Co t(5) = 1.00, p = .363; Hi t(5) = 0.61, p = .571) and total Aβ (B, 6E10, Co t(8) = 0.68, p = .515; Hi t(8) = 0.93, p = .378) plaques were not altered following AngIV-treatment in APP mice. Western blot measures of APP expression (pial t(6) = 0.92, p = .393; Co t(6) = 0.77, p = .470; Hi t(6) = 0.98, p = .363), soluble 56 kDa oligomeric species (pial t(6) = 0.38, p = .720; Co t(6) = 0.92, p = .392; Hi t(6) = 0.06, p = .951), and 9 kDa oligomeric species (Hi t(6) = 0.33, p = .753) were not significantly different following AngIV-treatment (C-E). Data were analyzed using a Student's t-test. n = 4-5 mice/group. Scale bar = 500 μm. Fig. 7 . AngIV treatment (T) normalized hippocampal AT1Rs, and elevated hippocampal AT4Rs in APP mice. Cortical (Co) AT1R levels were elevated in APP compared to WT and not altered by treatment (A, treatment F(1, 12) = 1.61, p = .229; genotype F(1, 12) = 6.70, p = .024; interaction F(1, 12) = 19.27, p < .001).
No difference was observed across genotype or treatment for Co AT2R (B, treatment F(1, 12) = 0.29, p = .603; genotype F(1, 12) = 0.01, p = .950; interaction F(1, 12) = 5.22, p = .041) or AT4R (C, IRAP, treatment F(1, 12) = 5.41, p = .038; genotype F(1, 12) = 0.83, p = .38). Hippocampal (Hi) AT1R was significantly elevated in APP mice compared to WT and normalized with AngIV (D, treatment F(1, 12) < 0.01, p = .999; genotype F(1, 12) = 9.88, p = .009). No difference was observed across genotype or treatment for Hi AT2R levels (E, treatment F(1, 12) = 0.16, p = .697; genotype F(1, 12) = 1.84, p = .201), whereas AngIV intervention significantly increased the AT4R in APP mice compared to APP controls (F, IRAP, treatment F(1, 12) = 5.11, p = .043; genotype F(1, 12) = 6.38, p = .027). Two-way ANOVAs were followed by Newman Keul's post-hoc multiple comparisons tests. n = 5 mice per group. *p < .05, **p < .01. vascular smooth muscle cell cultures (Esteban et al., 2005) , which may be due to the ability of AngIV to bind AT1R with low affinity (Bosnyak et al., 2011) , a mechanism that will require confirmation. AngIV, however, demonstrated potent antioxidant properties in brain cortical neurons, hence counteracting the Aβ-induced increased production of NADPH oxidase-derived reactive oxygen species that exert detrimental effects on neuronal function (Park et al., 2005) .
AngIV and cerebrovascular recovery
The potent antioxidant capacity of AngIV was further evidenced in brain vessels of APP mice as it restored cerebrovascular function and, particularly, endothelial cell function that is highly sensitive to Aβ-induced reactive oxygen species (Park et al., 2005) . AngIV reestablished dilatory function and NO bioavailability in brain vessels, which was associated with normalized endothelial TRPV4 channel function involving intermediate and small conductance Ca 2+ sensitive K + channels (Zhang et al., 2013b) , and m5 muscarinic ACh receptor-induced NO release (Elhusseiny and Hamel, 2000) . These benefits agree with the positive effects of AngIV on endothelial function and NO production in systemic or brain vessels (Kramar et al., 1998; Vinh et al., 2008 ). An-gIV's ability to activate eNOS through post-transcriptional modulation, facilitate NO synthesis and release from endothelial cells, and stimulate cGMP accumulation, provides mechanisms through which endothelial function may be rescued (Kramar et al., 1998; Royea et al., 2017; Vinh et al., 2008) . Supplemental benefits of AngIV on smooth muscle function were depicted by its restorative effects on CGRP-mediated dilation that involves smooth muscle KATP channels (Tong et al., 2009 ) and Ca 2+ activated K + channels (Vedernikov et al., 2002) . Restoring endothelial cell function likely also contributes to normalized sensoryevoked neurovascular coupling in AngIV-treated APP mice as this response relies on tight interaction between neurons, astrocytes and microvessels, including endothelial NO production (Chen et al., 2014) to efficiently couple CBF to changes in neuronal activity.
RAS receptors and AngIV treatment
AD patients display alterations in brain RAS peptide and receptor expression, including elevations in AngII and AT1Rs and decreased ACE activity (Kehoe et al., 2016; Savaskan et al., 2001) . Correspondingly, adult APP mice had elevated levels of cortical and hippocampal AT1Rs compared to WT, as previously found in older APP mice (Ongali et al., 2014) , an upregulation offset in AngIV-treated mice with normalized cognitive function. No difference was observed in AT2Rs indicating that AngIV benefits were most likely independent of AT2Rs. Despite being unaltered in the cortex, hippocampal AT4Rs were significantly reduced in APP mice and normalized by AngIV. Since AT4Rs are predominantly distributed in brain structures important to cognitive processing (Thomas and Mendelsohn, 2003) , including the hippocampus (Chow et al., 2015) , their normalization in this brain region following AngIVtreatment supports a mechanism related to memory rescue. Together with the high affinity of AngIV at AT4R (Chai et al., 2000) compared to AT1R and AT2R subtypes (Bosnyak et al., 2011; Nossaman et al., 1995) , and confirming AT4R-involvement in regulating brain perfusion (Kramar et al., 1997) , our findings point to AT4Rs as key mediators of the benefits seen in our study. The vehicle had no effect on any RAS receptor levels or experimental measures for either WT or APP mice. Future studies would benefit from assessing whether an AngIV scramble peptide could influence RAS receptor levels or biological markers.
Conclusion
Our results unequivocally demonstrate the pleiotropic ability of AngIV to mediate cognitive and cerebrovascular benefits in a transgenic mouse model of AD. They demonstrate multifaceted benefits of the AngIV cascade in mimicking many of the benefits observed with ARB treatment in AD animal models (Ongali et al., 2014; Royea et al., 2017) and patient populations (Mogi and Horiuchi, 2009; Villapol and Saavedra, 2015) . Our findings support the development of brain penetrant AngIV analogs as a therapeutic strategy in recovering neuronal and vascular impairments in AD.
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